BackgroundCD276 (B7-H3) is a pivotal immune checkpoint molecule with dual roles in T-cell regulation and tumor immune evasion, representing a promising therapeutic target across multiple cancers. However, a comprehensive analysis of the research landscape, evolutionary pathways, and knowledge structure in this field remains lacking.MethodsPublications related to CD276/B7-H3 in cancer research were systematically retrieved from the Web of Science Core Collection (WoS, n = 688) and Scopus (n = 759) spanning from January 2001 to August 2025.
After merging and de-duplication, a final corpus of 830 publications was analyzed using Bibliometrix, VOSviewer, CiteSpace, and Pajek to evaluate publication trends, influential authors and institutions, collaboration networks, core journals, co-citation patterns, and keyword evolution.ResultsThe field exhibited exponential growth with an annual publication increase of 21.77%. China and the United States were the dominant contributing countries.
Journal for Immunotherapy of Cancer was the most productive journal, while Clinical Cancer Research produced the most impactful publications. Co-citation analysis highlighted foundational studies on B7-H3’s prognostic significance and recent breakthroughs in CAR T-cell therapy targeting B7-H3.
Frontiers in Immunology published a clinical update in Infectious Disease on 01 Apr 2026.
The item focuses on From mechanism to clinical: research evolution and hotspot analysis of CD276/B7-H3 in cancer immunotherapy.
Review the original article for the full source wording and details.